CN106588565A - Synthesis method of chiral sec-allyl alcohol with hydroxyl ortho-position replaced with halogen atoms - Google Patents
Synthesis method of chiral sec-allyl alcohol with hydroxyl ortho-position replaced with halogen atoms Download PDFInfo
- Publication number
- CN106588565A CN106588565A CN201610881409.8A CN201610881409A CN106588565A CN 106588565 A CN106588565 A CN 106588565A CN 201610881409 A CN201610881409 A CN 201610881409A CN 106588565 A CN106588565 A CN 106588565A
- Authority
- CN
- China
- Prior art keywords
- hydroxyl
- allyl alcohol
- group
- chiral secondary
- halogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UTHAMCDUNPPWGL-VQCYPWCPSA-N NC[C@@H](/C=C/c1ccccc1)O Chemical compound NC[C@@H](/C=C/c1ccccc1)O UTHAMCDUNPPWGL-VQCYPWCPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
一种有机合成技术领域的利用改进的Julia烯烃化反应合成光学纯的手性仲烯丙醇的方法。具体技术路线为:将高光学纯的环氧卤丙烷经巯基四氮唑亲核开环后羟基保护、氧化成改进的Julia烯烃化试剂与醛或酮缩合、再脱除羟基保护得到一系列含有E式碳碳双键的、高光学纯的手性仲烯丙醇。A method for synthesizing optically pure chiral secondary allyl alcohol by utilizing an improved Julia olefination reaction in the technical field of organic synthesis. The specific technical route is: the highly optically pure epihalohydrin is subjected to nucleophilic ring-opening by mercaptotetrazolium, then the hydroxyl group is protected, oxidized into an improved Julia olefination reagent, condensed with aldehyde or ketone, and then the hydroxyl protection is removed to obtain a series of compounds containing E-type carbon-carbon double bond, highly optically pure chiral secondary allyl alcohol.
Description
技术领域:Technical field:
本发明属于有机合成化学领域,具体是一种羟基邻位为卤原子取代的手性仲烯丙醇的合成方法。The invention belongs to the field of organic synthesis chemistry, in particular to a method for synthesizing chiral secondary allyl alcohol in which the ortho position of a hydroxyl group is replaced by a halogen atom.
背景技术:Background technique:
手性仲烯丙醇及其衍生物片段广泛存在于许多天然产物和药物分子中,如用于降血脂的他汀(Statin)类药物,用于牛皮癣治疗的卡泊三醇(Calciprtriol),用于青光眼治疗的比马前列素(Bimatoprost),抗癌新药埃坡霉素(Epothilone)等。另外,具有光学活性的烯丙醇也是一类重要的反应中间体,可发生很多的化学转化,例如Claisen重排或者SN2’取代反应等。烯丙醇中C-O键的手性将诱导新生成的C-C键的手性,从而实现手性的传递。Chiral secondary allyl alcohol and its derivative fragments widely exist in many natural products and drug molecules, such as statin drugs for lowering blood lipids, calcipotriol for psoriasis treatment, and calcipotriol for psoriasis. Bimatoprost (Bimatoprost) for glaucoma treatment, new anti-cancer drug Epothilone (Epothilone), etc. In addition, optically active allyl alcohol is also an important class of reaction intermediates, which can undergo many chemical transformations, such as Claisen rearrangement or SN2' substitution reaction. The chirality of the C–O bond in allyl alcohol will induce the chirality of the newly generated C–C bond, thereby achieving the transfer of chirality.
基于手性仲烯丙醇结构的重要性,很多合成光学纯仲烯丙醇的方法被发展起来。如对消旋体的动力学拆分,烯基金属试剂对醛的不对称加成,α,β-烯基酮的不对称还原等。尽管合成手性仲烯丙醇的方法已经得到了很大的发展,但直接地高立体选择性地合成高对映选择性的仲烯丙醇仍是当今化学领域的极具挑战性的课题。对于羟基邻位卤原子取代的手性仲烯丙醇的合成则研究则更少,然而这些手性仲烯丙醇在一些手性药物成中又极其重要,并且这些化合物可以方便转化成手性的α,β-不饱和环氧乙烷。因此,寻求高效的合成高光学纯的、羟基邻位有取代基团的手性仲烯丙醇的方法就显得非常重要。Based on the importance of the structure of chiral secondary allyl alcohols, many methods for the synthesis of optically pure secondary allyl alcohols have been developed. Such as kinetic resolution of racemates, asymmetric addition of alkenyl metal reagents to aldehydes, asymmetric reduction of α, β-alkenyl ketones, etc. Although the methods for the synthesis of chiral secondary allyl alcohols have been greatly developed, the direct and high stereoselective synthesis of high enantioselective secondary allyl alcohols is still a very challenging topic in the field of chemistry today. There are fewer studies on the synthesis of chiral secondary allyl alcohols substituted by hydroxyl ortho-halogen atoms. However, these chiral secondary allyl alcohols are extremely important in the synthesis of some chiral drugs, and these compounds can be easily converted into chiral α,β-Unsaturated oxirane. Therefore, it is very important to find an efficient method for synthesizing highly optically pure chiral secondary allyl alcohols with substituent groups adjacent to the hydroxyl group.
发明内容:Invention content:
本发明的目的是针对现有技术的不足,提供一种羟基邻位为氯原子取代的手性仲烯丙醇的合成方法,解决现有手性仲烯丙醇的光学纯度不高、E式立体选择性不高、分离纯化难度较大及收率较低的技术问题。The purpose of the present invention is to aim at the deficiencies in the prior art, to provide a kind of synthesis method of chiral secondary allyl alcohol replaced by chlorine atom in the ortho position of the hydroxyl group, to solve the problem of low optical purity of existing chiral secondary allyl alcohol, E formula The technical problems of low stereoselectivity, greater difficulty in separation and purification, and lower yield.
本发明是通过以下技术方案实现的,本发明通过1-苯基-5-巯基四氮唑对环氧氯丙烷Ⅰ作用下亲核开环得到化合物Ⅲ。化合物III中羟基经保护试剂保护后得到化合物Ⅳ,经氧化反应后得到改进的Julia烯烃化试剂Ⅴ,与醛或酮在碱性条件下缩合得到化合物Ⅶ,进一步脱除羟基保护便得到含有E式碳碳双键的、高光学纯的手性仲烯丙醇。The present invention is achieved through the following technical scheme. In the present invention, compound III is obtained by nucleophilic ring opening under the action of 1-phenyl-5-mercaptotetrazolium on epichlorohydrin I. The hydroxyl group in compound III is protected by a protecting reagent to obtain compound IV, and the improved Julia olefination reagent V is obtained after oxidation reaction, which is condensed with aldehydes or ketones under basic conditions to obtain compound VII, and further deprotection of the hydroxyl group is obtained. Carbon-carbon double bond, highly optically pure chiral secondary allyl alcohol.
本发明的反应式可以表述如下:Reaction formula of the present invention can be expressed as follows:
其中化合物Ⅱ的用量为化合物Ⅰ用量的1.0-1.5倍,反应温度为-5~30℃。所述的化合物Ⅱ的用量优选为化合物Ⅰ的1.1倍,反应温度优选15~25℃。Wherein the dosage of compound II is 1.0-1.5 times of that of compound I, and the reaction temperature is -5-30°C. The dosage of compound II is preferably 1.1 times that of compound I, and the reaction temperature is preferably 15-25°C.
所述的羟基保护得到化合物Ⅳ,其反应式为:Described hydroxyl protection obtains compound IV, and its reaction formula is:
所述的烃类溶剂为二氯甲烷、三氯甲烷或二氯乙烷,优选二氯甲烷。所述的碱为三乙胺、咪唑、氢化钠、吡啶,优选咪唑。所述的催化剂为4-二甲氨基吡啶、甲磺酸、Ru3(CO)12,优选4-二甲氨基吡啶。The hydrocarbon solvent is dichloromethane, chloroform or dichloroethane, preferably dichloromethane. The base is triethylamine, imidazole, sodium hydride, pyridine, preferably imidazole. The catalyst is 4-dimethylaminopyridine, methanesulfonic acid, Ru 3 (CO) 12 , preferably 4-dimethylaminopyridine.
所述的氧化反应得到化合物砜Ⅴ,其反应式为:Described oxidation reaction obtains compound sulfone V, and its reaction formula is:
所述的醇类溶剂为甲醇、乙醇、异丙醇、丙醇或正丁醇,优选为乙醇。The alcoholic solvent is methanol, ethanol, isopropanol, propanol or n-butanol, preferably ethanol.
所述的氧化剂的为间氯过氧苯甲酸或四水合钼酸铵/30%双氧水体系,优选四水合钼酸铵/30%双氧水体系。The oxidizing agent is m-chloroperoxybenzoic acid or ammonium molybdate tetrahydrate/30% hydrogen peroxide system, preferably ammonium molybdate tetrahydrate/30% hydrogen peroxide system.
所述的碱性条件下反应是指:在醚类溶剂中,在碱的作用下进行缩合反应,其反应式如下所示:Reaction under described basic conditions refers to: in ether solvent, carry out condensation reaction under the effect of alkali, and its reaction formula is as follows:
其中:化合物Ⅵ的用量为化合物Ⅴ的1.0-1.8倍,反应温度为-78~0℃。Wherein: the amount of compound VI is 1.0-1.8 times that of compound V, and the reaction temperature is -78-0°C.
所述的化合物Ⅵ用量优选为化合物Ⅴ的1.5倍,反应温度优选为-78~-60℃.The amount of compound VI is preferably 1.5 times that of compound V, and the reaction temperature is preferably -78~-60°C.
所述的醚类溶剂为四氢呋喃、乙醚、甲基叔丁基醚、乙二醇二甲醚,优选为四氢呋喃。The ether solvent is tetrahydrofuran, diethyl ether, methyl tert-butyl ether, ethylene glycol dimethyl ether, preferably tetrahydrofuran.
所述的碱为二异丙基氨基锂(LDA)、双(三甲基硅基)氨基钠(NaHMDS)、双(三甲基硅基)氨基钾(KHMDS)、双(三甲基硅基)氨基锂(LiHMDS)、正丁基锂(n-BuLi)。优选双(三甲基硅基)氨基钠(NaHMDS)。The base is lithium diisopropylamide (LDA), sodium bis(trimethylsilyl)amide (NaHMDS), potassium bis(trimethylsilyl)amide (KHMDS), bis(trimethylsilyl) ) lithium amide (LiHMDS), n-butyl lithium (n-BuLi). Sodium bis(trimethylsilyl)amide (NaHMDS) is preferred.
所述的脱除羟基保护,是指在酸性或者碱性条件下得到E式的光学纯的手性仲烯丙醇,其反应式为:The deprotection of the hydroxyl group refers to obtaining the optically pure chiral secondary allyl alcohol of the E formula under acidic or alkaline conditions, and its reaction formula is:
所述的酸或者碱为氢氟酸、氢氟酸吡啶、四丁基氟化铵、四丁基溴化铵、四溴化碳。优选四丁基氟化铵。The acid or base is hydrofluoric acid, pyridinium hydrofluoride, tetrabutylammonium fluoride, tetrabutylammonium bromide, carbon tetrabromide. Preference is given to tetrabutylammonium fluoride.
本发明的有益效果是:通过本发明的方法,可以在比较温和的反应条件下,以比较低的成本合成高光学纯度的、高E式立体选择性的手性仲烯丙醇,为药物中间体的合成、以及相关有机合成提供一种经济、便利的方法。The beneficial effects of the present invention are: by the method of the present invention, chiral secondary allyl alcohol with high optical purity and high E stereoselectivity can be synthesized at a relatively low cost under relatively mild reaction conditions, which is a drug intermediate It provides an economical and convenient method for the synthesis of body and related organic synthesis.
具体实施方式detailed description
下面对本发明的实施例做详细说明:本实施例在以本发明技术方案为前提下进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。The embodiments of the present invention are described in detail below: the present embodiment is implemented under the premise of the technical solution of the present invention, and detailed implementation methods and specific operating procedures are provided, but the protection scope of the present invention is not limited to the following implementation example.
1、(R)-1-氯-3-(1-苯基-5-巯基四唑)-2–丙醇的合成反应式:1. The synthetic reaction formula of (R)-1-chloro-3-(1-phenyl-5-mercaptotetrazole)-2-propanol:
操作步骤Steps
1000mL的圆底烧瓶中加入1-苯基-5-巯基四氮唑(50g,280.6mmol)、甲醇(350mL)、环氧氯丙烷(23mL,294.6mmol)及三乙胺(59mL,420.8mmol),室温下搅拌反应过夜。浓缩反应液,加入150mL乙酸乙酯,分别用水、0.1M盐酸、饱和NaHCO3,饱和食盐水洗涤,分液,有机相用无水硫酸镁干燥、过滤、浓缩得到产品Ⅲ(70.5g,96%)。Add 1-phenyl-5-mercaptotetrazolium (50g, 280.6mmol), methanol (350mL), epichlorohydrin (23mL, 294.6mmol) and triethylamine (59mL, 420.8mmol) into a 1000mL round bottom flask , and the reaction was stirred overnight at room temperature. Concentrate the reaction solution, add 150mL ethyl acetate, wash with water, 0.1M hydrochloric acid, saturated NaHCO 3 , and saturated brine respectively, separate the layers, dry the organic phase with anhydrous magnesium sulfate, filter, and concentrate to obtain product III (70.5g, 96% ).
2、5-(2-(叔丁基二甲基甲硅烷氧基)-3-氯丙基)-1-苯基四氮唑的合成反应式:2. The synthetic reaction formula of 5-(2-(tert-butyldimethylsilyloxy)-3-chloropropyl)-1-phenyltetrazolium:
操作步骤Steps
1000mL的圆底烧瓶中加入1-氯-3-(1-苯基-5-硫基四唑)-2–丙醇(130g,480.2mmol),CH2Cl2(500mL),冰浴条件下,加入DMAP(5.8g,48mmol),咪唑(65.3g,960.4mmol),叔丁基二甲基氯硅烷(79.6g,528.2mmol)。室温下搅拌过夜。加入水200mL,CH2Cl2(2×100mL)萃取反应液,饱和食盐水洗涤,无水硫酸钠干燥、过滤、浓缩,重结晶得到产品Ⅳ(170.1g,92%)。1H NMR(400MHz,CDCl3):δ7.58(s,5H),4.33-4.38(m,1H),3.56-3.71(m,4H),0.88(s,9H),0.11(s,3H),0.08(s,3H).13C NMR(400MHz,CDCl3):δ154.1,133.6,130.2,129.8,123.8,70.1,47.4,37.7,25.7,18.01,-4.6,-4.7Add 1-chloro-3-(1-phenyl-5-thiotetrazole)-2-propanol (130g, 480.2mmol) and CH 2 Cl 2 (500mL) in a 1000mL round bottom flask, under ice bath condition , DMAP (5.8g, 48mmol), imidazole (65.3g, 960.4mmol), tert-butyldimethylsilyl chloride (79.6g, 528.2mmol) were added. Stir overnight at room temperature. Add 200 mL of water, extract the reaction solution with CH 2 Cl 2 (2×100 mL), wash with saturated brine, dry over anhydrous sodium sulfate, filter, concentrate, and recrystallize to obtain product IV (170.1 g, 92%). 1 H NMR (400MHz, CDCl 3 ): δ7.58(s,5H),4.33-4.38(m,1H),3.56-3.71(m,4H),0.88(s,9H),0.11(s,3H) ,0.08(s,3H). 13 C NMR(400MHz,CDCl 3 ):δ154.1,133.6,130.2,129.8,123.8,70.1,47.4,37.7,25.7,18.01,-4.6,-4.7
3、5-(2-(叔丁基二甲基甲硅烷氧基)-3-氯丙基)-1-苯基四氮唑砜的合成反应式:3. The synthetic reaction formula of 5-(2-(tert-butyldimethylsilyloxy)-3-chloropropyl)-1-phenyltetrazolium sulfone:
500mL圆底烧瓶中加入5-(2-(叔丁基二甲基甲硅烷氧基)-3-氯丙基)-1-苯基四氮唑(50g,129.9mmol),乙醇(100mL),冰浴条件下,加入四水合钼酸铵(32.1g,26.0mmol),30%过氧化氢水溶液(118mL,104mmol),室温下搅拌反应4h,加入饱和亚硫酸钠50mL,乙酸乙酯(3×100mL)萃取反应液,饱和食盐水洗涤,无水硫酸镁干燥、过滤、浓缩,柱层析纯化得到产品Ⅴ(43.6g,80.5%)。1HNMR(400MHz,CDCl3):δ7.60-7.69(m,5H),4.64(t,J=5.2Hz,1H),4.1(t,J=5.2Hz,2H),3.65(dd,J1=4.4Hz,J2=1.2Hz,2H),0.85(s,9H),0.11(s,3H),0.05(s,3H).13C NMR(400MHz,CDCl3):δ154.1,133.0,131.5,129.8,125.1,67.1,60.0,47.4,25.6,17.9.Add 5-(2-(tert-butyldimethylsilyloxy)-3-chloropropyl)-1-phenyltetrazolium (50g, 129.9mmol), ethanol (100mL) into a 500mL round bottom flask, Under ice-bath condition, add ammonium molybdate tetrahydrate (32.1g, 26.0mmol), 30% hydrogen peroxide aqueous solution (118mL, 104mmol), stir at room temperature for 4h, add saturated sodium sulfite 50mL, ethyl acetate (3×100mL) The reaction solution was extracted, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, concentrated, and purified by column chromatography to obtain product V (43.6 g, 80.5%). 1 HNMR (400MHz, CDCl 3 ): δ7.60-7.69 (m, 5H), 4.64 (t, J = 5.2Hz, 1H), 4.1 (t, J = 5.2Hz, 2H), 3.65 (dd, J 1 =4.4Hz, J 2 =1.2Hz, 2H), 0.85(s, 9H), 0.11(s, 3H), 0.05(s, 3H). 13 C NMR (400MHz, CDCl 3 ): δ154.1, 133.0, 131.5, 129.8, 125.1, 67.1, 60.0, 47.4, 25.6, 17.9.
4、1-苯基-3-叔丁基二甲基甲硅烷氧基-4-氯丁烯的合成反应式:4. The synthetic reaction formula of 1-phenyl-3-tert-butyldimethylsilyloxy-4-chlorobutene:
100mL的三口烧瓶中,加入5-(2-(叔丁基二甲基甲硅烷氧基)-3-氯丙基)-1-苯基四氮唑砜(0.8g,1.9mmol),苯甲醛(0.29mL,2.9mmol),THF(10mL)冷却至-78℃,通过注射器加入NaHMDS(1.0M四氢呋喃溶液,2eq)。反应液在-78℃条件下搅拌30min,置于室温下反应1h。加入饱和NaHCO3,乙酸乙酯(3×15mL)萃取反应液,饱和食盐水洗涤,无水硫酸镁干燥,过滤,浓缩,柱层析得到产品Ⅵ(0.54g,95%)。1H NMR(400MHZ,CDCl3)δ7.14-7.30(m,5H),6.54(d,J=15.6Hz,1H),6.09(dd,J1=16Hz,J2=6.4Hz,1H),4.36(dd,J1=11.6,J2=5.6Hz,1H),3.41(dd,J1=6.4Hz,J2=2.8Hz,2H),0.84(s,9H),0.04(s,3H),0.00(s,3H).13CNMR(400MHz,CDCl3):δ136.5,131.7,129.2,128.6,127.8,126.6,73.9,49.0,25.8,18.3,-4.4,-4.7.In a 100mL three-necked flask, add 5-(2-(tert-butyldimethylsilyloxy)-3-chloropropyl)-1-phenyl tetrazolium sulfone (0.8g, 1.9mmol), benzaldehyde (0.29mL, 2.9mmol), THF (10mL) was cooled to -78°C, and NaHMDS (1.0M solution in tetrahydrofuran, 2eq) was added via syringe. The reaction solution was stirred at -78°C for 30 min, and left at room temperature for 1 h. Add saturated NaHCO 3 , extract the reaction solution with ethyl acetate (3×15 mL), wash with saturated brine, dry over anhydrous magnesium sulfate, filter, concentrate, and column chromatography to obtain product VI (0.54 g, 95%). 1 H NMR (400MHZ, CDCl 3 ) δ7.14-7.30 (m, 5H), 6.54 (d, J = 15.6Hz, 1H), 6.09 (dd, J 1 = 16Hz, J 2 = 6.4Hz, 1H), 4.36(dd, J 1 =11.6, J 2 =5.6Hz, 1H), 3.41(dd, J 1 =6.4Hz, J 2 =2.8Hz, 2H), 0.84(s, 9H), 0.04(s, 3H) ,0.00(s,3H). 13 CNMR(400MHz,CDCl 3 ):δ136.5,131.7,129.2,128.6,127.8,126.6,73.9,49.0,25.8,18.3,-4.4,-4.7.
5、1-苯基-3-羟基-4-氯丁烯的合成反应式:5. The synthetic reaction formula of 1-phenyl-3-hydroxy-4-chlorobutene:
操作步骤Steps
50mL圆底烧瓶中,加入1-苯基-3-叔丁基二甲基甲硅烷氧基-4-氯丁烯(0.3mmol,0.1g,1.0eq)加入加入THF溶液5mL,称取四丁基氟化铵(0.7mmol,0.1g,1.0eq)冰浴条件加入至反应液中,搅拌反应10min,置于室温下反应1h后,向反应液中加入5mL饱和碳酸氢钠,洗涤反应液一次。然后向水相中加入8mL乙酸乙酯萃取溶解在水相中的产物,收集有机相后,无水硫酸钠干燥、浓缩、柱层析得到产品Ⅶ(0.5g,82%)。1H NMR(400MHZ,CDCl3):δ7.24-7.40(m,5H),6.72(dd,J1=16Hz,J2=0.8Hz,1H),6.20(dd,J1=16Hz,J2=0.8Hz,1H),6.20(dd,J1=16Hz,J2=6Hz,1H),4.51-4.55(m,1H),3.71(dd,J1=11.2Hz,J2=4Hz,1H),3.59(dd,J1=11.2Hz,J2=7.6Hz,1H),2.44(s,1H).13C NMR(400MHz,CDCl3):δ136.0,132.8,128.7,127.2,126.7,72.3,49.7.In a 50mL round bottom flask, add 1-phenyl-3-tert-butyldimethylsilyloxy-4-chlorobutene (0.3mmol, 0.1g, 1.0eq) and add 5mL of THF solution, weigh tetrabutylene Ammonium fluoride (0.7mmol, 0.1g, 1.0eq) was added to the reaction solution in an ice bath, stirred for 10 minutes, and left at room temperature for 1 hour, then 5 mL of saturated sodium bicarbonate was added to the reaction solution, and the reaction solution was washed once. . Then 8 mL of ethyl acetate was added to the aqueous phase to extract the product dissolved in the aqueous phase. After collecting the organic phase, it was dried over anhydrous sodium sulfate, concentrated, and column chromatographed to obtain product VII (0.5 g, 82%). 1 H NMR (400MHZ, CDCl 3 ): δ7.24-7.40 (m, 5H), 6.72 (dd, J 1 = 16Hz, J 2 = 0.8Hz, 1H), 6.20 (dd, J 1 = 16Hz, J 2 = 0.8Hz, 1H), 6.20 (dd, J 1 = 16Hz, J 2 = 6Hz, 1H), 4.51-4.55 (m, 1H), 3.71 (dd, J 1 = 11.2Hz, J 2 = 4Hz, 1H) , 3.59 (dd, J 1 =11.2Hz, J 2 =7.6Hz, 1H), 2.44 (s, 1H). 13 C NMR (400MHz, CDCl 3 ): δ136.0, 132.8, 128.7, 127.2, 126.7, 72.3, 49.7 .
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610881409.8A CN106588565A (en) | 2016-10-09 | 2016-10-09 | Synthesis method of chiral sec-allyl alcohol with hydroxyl ortho-position replaced with halogen atoms |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610881409.8A CN106588565A (en) | 2016-10-09 | 2016-10-09 | Synthesis method of chiral sec-allyl alcohol with hydroxyl ortho-position replaced with halogen atoms |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106588565A true CN106588565A (en) | 2017-04-26 |
Family
ID=58555839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610881409.8A Pending CN106588565A (en) | 2016-10-09 | 2016-10-09 | Synthesis method of chiral sec-allyl alcohol with hydroxyl ortho-position replaced with halogen atoms |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106588565A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101255100A (en) * | 2008-03-18 | 2008-09-03 | 武汉科技学院 | The synthetic method of allyl glycidyl ether |
CN104592166A (en) * | 2014-12-31 | 2015-05-06 | 湖北绿色家园精细化工有限责任公司 | Immobilized catalytic synthesis method of allyl glycidyl ether molecular sieve |
-
2016
- 2016-10-09 CN CN201610881409.8A patent/CN106588565A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101255100A (en) * | 2008-03-18 | 2008-09-03 | 武汉科技学院 | The synthetic method of allyl glycidyl ether |
CN104592166A (en) * | 2014-12-31 | 2015-05-06 | 湖北绿色家园精细化工有限责任公司 | Immobilized catalytic synthesis method of allyl glycidyl ether molecular sieve |
Non-Patent Citations (1)
Title |
---|
江珊等: "匹伐他汀关键手性中间体的立体选择性合成 ", 《广州化工》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH01305076A (en) | Preparation of taxol | |
KR20140035484A (en) | Method of producing beraprost | |
CN102630226A (en) | Entecavir synthesis method and intermediate compound thereof | |
JP2010037289A (en) | Trifunctional nitrile oxide and method for producing the same | |
JP5646706B2 (en) | Method for producing C-glycoside derivative | |
JP2002533430A (en) | Preparation method of aryl ether | |
WO2003042180A9 (en) | Process for producing optically active oxoheptenoic acid ester | |
US11046663B2 (en) | Entecavir intermediate, synthetic method thereof and synthetic method for entecavir | |
CN103554064B (en) | The preparation method of 3-hydroxyl oxygen heterocycle butane | |
CN106588565A (en) | Synthesis method of chiral sec-allyl alcohol with hydroxyl ortho-position replaced with halogen atoms | |
JP3646651B2 (en) | Method for producing butanetriol derivatives | |
CN109232637B (en) | Preparation method of entecavir intermediate | |
US20210054003A1 (en) | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | |
RU2434860C1 (en) | Method of producing (6r)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one and intermediate compound used in present method | |
CN107353266B (en) | A kind of preparation method that olefin(e) acid bromine lactonizes | |
CN113461659B (en) | C-spirocyclic prostaglandin analogue intermediate and preparation method thereof | |
US9227948B2 (en) | Process for the preparation of 2-substituted-2-(6-(substituted)-7-methylbenzo[D][1,3]dioxol-4-yl)acetic acid derivatives | |
CN113292630B (en) | Methods for Asymmetric Synthesis of Triptonide and Triptolide | |
CN111662318B (en) | Iloprost key intermediate and preparation method thereof | |
JP2002105045A (en) | Precursor of bongkrekic acid and method for producing the same | |
CN118063463A (en) | Preparation method of entecavir | |
CN118666669A (en) | Efficient asymmetric synthesis method of sitafloxacin intermediate (1S, 2S) -2-fluorocyclopropyl carboxylic acid | |
JPS623840B2 (en) | ||
WO2014108011A1 (en) | Entecavir intermediates and preparation method thereof | |
CN117510445A (en) | Intermediate of beraprost and salt thereof and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170426 |
|
WD01 | Invention patent application deemed withdrawn after publication |